Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas

Cancer Management and Research

Volumn 9, Issue , 2017, Pages 821-837

  Xu, Peng ^a   Zhao, Yang ^a   Liu, Kang ^a   Lin, Shuai ^a   Liu, Xinghan ^a   Wang, Meng ^a   Yang, Pengtao ^a   Tian, Tian ^a   Zhu, Yu Yao ^a   Dai, Zhijun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Carcinomas; Meta analysis; Prognosis; TROP2

Indexed keywords

CELL SURFACE PROTEIN; TROPHOBLAST CELL SURFACE ANTIGEN 2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CLINICAL OUTCOME; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; NONHUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION;

EID: 85041500292     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S147033     Document Type: Article

References (70)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Wang C, Zhang J, Cai M, et al. DBGC: A Database of Human Gastric Cancer. PLoS One. 2015;10(11):e0142591.
3. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365(9454):153–165.
4. McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum. 2005;48(8):1632–1650.
5. Wu DH, Liu L, Chen LH. Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells. World J Gastroenterol. 2005;11(20): 3051–3055.
6. Aggarwal S, Chu E. Current therapies for advanced colorectal cancer. Oncology (Williston Park, NY). 2005;19(5):589–595.
7. Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acadof Sci U S A. 1981;78(8):5147–5150.
8. McDougall AR, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Trop2: from development to disease. Dev Dyn. 2015;244(2):99–109.
9. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.
10. Fornaro M, Arciprete RD, Stella M, et al. Cloning of the gene encoding TROP-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer. 1995;62(5):610–618.
11. Guerra E, Trerotola M, Dell’ Arciprete R, et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 2008;68(19):8113–8121.
12. Ju X, Jiao X, Ertel A, et al. v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res. 2016;76(22):6723–6734.
13. Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One. 2013;8(9):e75864.
14. Nakanishi H, Taccioli C, Palatini J, et al. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene. 2014;33(6):702–712.
15. Pak MG, Shin DH, Lee CH, Lee MK. Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol. 2012;10:53.
16. Ripani E, Sacchetti A, Corda D, Alberti S. Human TROP-2 is a tumor-associated calcium signal transducer. Int J Cancer. 1998;76(5):671–676.
17. Sawanyawisuth K, Tantapotinan N, Wongkham C, et al. Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma. Ann Hepatol. 2016;15(1):71–81.
18. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev. 2012;26(20):2271–2285.
19. Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222–233.
20. Trerotola M, Ganguly KK, Fazli L, et al. Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget. 2015;6(16):14318–14328.
21. Wang XD, Wang Q, Chen XL, et al. Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway. Mol Med Rep. 2015;12(1):865–870.
22. Wanger TM, Dewitt S, Collins A, Maitland NJ, Poghosyan Z, Knauper V. Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cell Signal. 2015;27(7):1325–1335.
23. Yang J, Zhu Z, Wang H, Li F, Du X, Ma RZ. Trop2 regulates the proliferation and differentiation of murine compact-bone derived MSCs. Int J Oncol. 2013;43(3):859–867.
24. Wang H, Liu Q, Tang X, et al. Eukaryotic expression of human anti-TROP2 antibody IgG and its inhibitory effect on cell proliferation of pancreatic cancer. J Nanjing Med Univ Nat Sci Ed. 2014;34(7):863–869,882.
25. van Rij CM, Frielink C, Sharkey RM, et al. FDG-PET and pretargeted immunoPET of prostate cancer with an anti-TROP2 x anti-HSG bispecific antibody in a nude mouse model. Eur J Nucl Med Mol Imaging. 2012;39:S194-S195.
26. van Rij CM, Frielink C, Goldenberg DM, et al. Pretargeted Radioim-munotherapy of Prostate Cancer with an Anti-TROP-2xAnti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. Cancer Biother Radiopharm. 2014;29(8):323–329.
27. van Rij CM, Frielink C, Goldenberg DM, et al. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts. Mol Imaging Biol. 2015;17(1):94–101.
28. Mao Y, Wang X, Zheng F, et al. The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer. Oncotarget. 2016;7(17):24810–24823.
29. Liu X, Li S, Yi F. Trop2 gene: a novel target for cervical cancer treatment. J Cancer Res Clin Oncol. 2014;140(8):1331–1341.
30. Liu T, Tian J, Chen Z, et al. Anti-TROP2 conjugated hollow gold nano-spheres as a novel nanostructure for targeted photothermal destruction of cervical cancer cells. Nanotechnology. 2014;25(34):345103.
31. Lin H, Zhang H, Wang J, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014;134(5): 1239–1249.
32. Farivar TN, Najafipour R, Johari P. Nano - drug Delivery of Apoptosis Activator 2 to AGS Cells by Liposomes Conjugated with Anti-TROP2 Antibody. N Am J Med Sci. 2012;4(11):582–585.
33. Alberti S, Trerotola M, Dell’ AR, et al. Selective killing of human cancer cells by targeting a fusion mRNA between CYCLIN D1 and TROP2. J Clin Oncol. 2009;27(15_suppl):e14569.
34. Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46(5):944–953.
35. Bignotti E, Zanotti L, Calza S, et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol. 2012;12(1):22.
36. Chen M-B, Wu H-F, Zhan Y, et al. Prognostic value of TROP2 expression in patients with gallbladder cancer. Tumor Biol. 2014;35(11): 11565–11569.
37. Chen R, Lu M, Wang J, et al. Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type. Virchows Archiv. 2013;463(5):713.
38. Fang YJ, Lu ZH, Wang GQ, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009;24(8): 875–884.
39. Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99(8): 1290–1295.
40. Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008;21(2):186–191.
41. Guan GF, Zhang DJ, Wen LJ, et al. Prognostic value of TROP2 in human nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2015;8(9): 10995–11004.
42. Hao W, Huiming Xu MS, Shu ZM, et al. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck. 2013;35(10):1373–1378.
43. Kobayashi H, Minami Y, Anami Y, et al. Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. Virchows Archiv. 2010;457(1):69–76.
44. Muhlmann G, Spizzo G, Gostner J, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009;62(2): 152–158.
45. Ning S, Guo S, Xie J, Xu Y, Lu X, Chen Y. TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg. 2013;17(2):360–368.
46. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006;12(10):3057–3063.
47. Zeng P, Chen MB, Zhou LN, Tang M, Liu CY, Lu PH. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis. Sci Rep. 2016;6:33658.
48. Jiang A, Gao X, Zhang D, Zhang L, Lu H. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol Lett. 2013;6(2):375–380.
49. Ambrogi F, Fornili M, Boracchi P, et al. Trop-2 Is a Determinant of Breast Cancer Survival. PLos One. 2014;9(5):e96993.
50. Lin H, Huang JF, Qiu JR, et al. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol. 2013;94(1):73–78.
51. Zhou ZR, Zhang TS, Bo LI, Mao Z, Zeng XT, Liu SX. Extracting and transforming of appropriate data of Meta-analysis in survival curve. Chin J Evid-Based Cardiovasc Med. 2014;6(3):243–247.
52. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–560.
53. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
54. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
55. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8(17):28725–28735.
56. Xu N, Zhang Z, Zhu J, et al. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma. Int J Exp Pathol. 2016;97(2):150–158.
57. Zhang L, Yang G, Jiang H, et al. TROP2 is associated with the recurrence of patients with non-muscle invasive bladder cancer. Int J Clin Exp Med. 2017;10(1):1643–1650.
58. Yuan G. Expression and significance of TROP2 in the non-muscleinvasive bladder transitional cell Cancer [Master Thesis], Soochow University; 2015.
59. Chen X, Pang B, Liang Y, et al. Overexpression of EpCAM and Trop2 in pituitary adenomas. Int J Clin Exp Pathol. 2014;7(11): 7907–7914.
60. Li XX, Teng SF, Xu K, et al. Expression of trophoblast cell-surface antigen 2, phosphorylated extracellular signal-regulated kinase 1/2, and cyclin D1 in gallbladder carcinoma tissue and related clinical significance. J Clin Hepatol. 2017;33(5):909–914.
61. Wu H, Xu H, Zhang S, et al. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck. 2013;35(10):1373–1378.
62. Xu KY, Gu J. Expression of TROP2 mRNA in left-sided and right-sided colon cancer and its clinical significance. Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12(3):285–289. Chinese.
63. Zhao P, Chen J, Cao W, et al. The expression and clinical significance of TROP-2 protein in colon cancer. Chongqing Med. 2016;45(35):4963–4966.
64. Zhao W, Zhu H, Zhang S, et al. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 2016;7(5):6136–6145.
65. Shi X. Comparison of the Power Difference of Egger’s Test and Begg’s Test and the Reason Analysis. Acta Med Univ Sci Et Technologiae Huazhong. 2009;38(1):91–93.
66. Tsukahara Y, Tanaka M, Miyajima A. TROP2 expressed in the trunk of the ureteric duct regulates branching morphogenesis during kidney development. PLos One. 2011;6(12):e28607.
67. Mustata RC, Vasile G, Fernandezvallone V, et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep. 2013;5(2):421.
68. Trerotola M, Alberti S, Languino LR. Trop2 modulates beta1 integrin-mediated adhesion and migration of prostate cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting. 2010;51:1246–1246.
69. Wang J, Zhang K, Grabowska D, et al. Loss of Trop2 promotes carcino-genesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res. 2011;9(12):1686–1695.
70. Lin JC, Wu YY, Wu JY, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012;4(6):472–485